Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

Although most patients with epithelial ovarian cancer respond to frontline platinum-based chemotherapy, around 70% will relapse within 3 years. The phase 3 JAVELIN Ovarian 100 trial compared avelumab (anti-PD-L1 monoclonal antibody) in combination with chemotherapy followed by avelumab maintenance,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2021-09, Vol.22 (9), p.1275-1289
Hauptverfasser:	Monk, Bradley J, Colombo, Nicoletta, Oza, Amit M, Fujiwara, Keiichi, Birrer, Michael J, Randall, Leslie, Poddubskaya, Elena V, Scambia, Giovanni, Shparyk, Yaroslav V, Lim, Myong Cheol, Bhoola, Snehalkumar M, Sohn, Joohyuk, Yonemori, Kan, Stewart, Ross A, Zhang, Xiaoxi, Perkins Smith, Julia, Linn, Carlos, Ledermann, Jonathan A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antibodies Cancer therapies Carboplatin Chemotherapy Committees Fallopian tube Fibrillation Gastric cancer Immunotherapy Leukocytes (neutrophilic) Lymphocytes Monoclonal antibodies Neutropenia Ovarian cancer Paclitaxel Patients PD-L1 protein Peritoneum Surgery Targeted cancer therapy Tumors Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!